Table 1 Patient characteristics according to the presence of CPFE
Variable | IPF-NSCLC | CPFE-NSCLC | P-value |
|---|---|---|---|
Number of patients, n (%) | 176 (62.2%) | 107 (37.8%) | Â |
Age, years | 70.4 ± 8.4 (46–89) | 70.1 ± 7.1 (51–87) | 0.810 |
Sex, men | 165 (93.8%) | 104 (97.2%) | 0.263 |
BMI, kg/m2 | 23.4 ± 3.2 (15.2–30.7) | 22.9 ± 3.2 (13.3–29.8) | 0.222 |
Ever smoker, % | 161 (91.5%) | 103 (96.3%) | 0.145 |
Smoking history, pack-years | 35.6 ± 23.8 (0–120) | 46.4 ± 26.4 (0–180) | <  0.001 |
Histology, numbers (%) | Â | Â | 0.344 |
 Adenocarcinoma | 67 (38.1%) | 50 (46.7%) |  |
 Squamous cell carcinoma | 84 (47.7%) | 45 (42.1%) |  |
 Others | 25 (14.2%) | 12 (11.2%) |  |
FVC, % predicted | 83.3 ± 18.8 (34–125) | 82.8 ± 17.4 (41–121) | 0.844 |
FEV1, % predicted | 90.2 ± 20.7 (5–140) | 86.0 ± 18.7 (44–135) | 0.091 |
DLCO, % predicted (n = 249) | 78.0 ± 21.5 (33–128) | 64.8 ± 17.9 (16–102) | <  0.001 |
FEV1/FVC, Percentage | 75.1 ± 8.4 (48.2–96.3) | 71.2 ± 9.6 (16–102) | 0.001 |
NSCLC Stage, numbers (%) | Â | Â | 0.617 |
 Stage I | 45 (25.6%) | 27 (25.2%) |  |
 Stage II | 27 (15.3%) | 13 (12.1%) |  |
 Stage III | 38 (21.6%) | 30 (28.0%) |  |
 Stage IV | 66 (37.5%) | 37 (34.6%) |  |
ECOG ≥2, n (%) | 38 (21.6%) | 16 (15.0%) | 0.106 |
Follow-up time, months | 24.1 ± 24.1 (0.0–138.0) | 18.6 ± 25.5 (0.3–137.8) | 0.975 |
Time Gap between Diagnosis of IPF or CPFE and Diagnosis of NSCLC, months | 16.4 ± 30.7 (0–149.6) | 16.1 ± 31.1 (0–148.4) | 0.937 |
GAP Index score | 3.17 ± 1.19 (1–8) | 3.38 ± 1.21 (1–7) | 0.166 |
Received chemotherapy, n (%) | 78 (44.3%) | 53 (49.5%) | 0.461 |
Received operation, n (%) | 73 (41.7%) | 37 (34.9%) | 0.313 |
Received radiotherapy, n (%) | 24 (13.6%) | 20 (18.7%) | 0.310 |
AE, n (%)a | 19 (12.5%) | 19 (21.3%) | 0.098 |